Neurim Pharmaceuticals (1991) Ltd v Generic Partners Pty Ltd (No 5)

Neurim Pharmaceuticals (1991) Ltd sued Generic Partners Pty Ltd for alleged patent infringements in relation to a patent concerning a method of treatment for primary insomnia characterized by non-restorative sleep and for improving restorative quality of sleep. The dispute was heard and determined by the Federal Court of Australia.

The primary legal issues in the case were the validity of the patent claims, the interpretation of specific terms within the claims, and whether the respondents' product or actions constituted an infringement of the patent. The court needed to determine the meaning of terms such as "non-restorative sleep" and "restorative quality of sleep" as used in the patent claims, particularly when read in conjunction with the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Additionally, the court had to decide whether the respondents' product, which could be used for non-infringing methods of treatment, infringed the patent, and whether the respondents had authorized the infringement through medical practitioners.

The court held that the claims of the patent were valid and sufficiently clear. It found that the respondents' product did infringe the method of treatment claims by being supplied and by the authorization of medical practitioners to use the product for the patented indication. The court rejected the argument that the respondents' product was a staple commercial product, which could have potentially negated the infringement. It also found that the respondents' product information document and approved indication did not constitute a statement or inducement to use the product in a manner that would infringe the patent. The court concluded that the Swiss-style claims were infringed as the respondents' product was a medicament used for treating primary insomnia characterized by non-restorative sleep and improving restorative quality of sleep. The court found that the respondents had authorized the infringement of the method of treatment claims by medical practitioners prescribing their product for the patented indication, even though the patented and approved indications differed.

The court ordered the parties to provide proposed short minutes of order and to notify the court of any disagreements regarding the scope of the orders. The proceeding was stand over for further orders.